Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease-Reference-Cited by-同舟云学术

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn’s Disease

Published:2018-07 Issue:1 Volume:155 Page:76-87
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Danese Silvio,Bonovas Stefanos^ORCID,Lopez Anthony,Fiorino Gionata^ORCID,Sandborn William J.,Rubin David T.,Kamm Michael A.,Colombel Jean-Frederic,Sands Bruce E.,Vermeire Severine,Panes Julian^ORCID,Rogler Gerhard,D’Haens Geert,Peyrin-Biroulet Laurent

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference117 articles.

1. Crohn’s disease;Torres;Lancet,2017

2. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome;Fiorino;J Crohns Colitis,2017

3. Factors promoting development of fibrosis in Crohn’s disease;Rogler;Front Med,2017

4. Biomarkers of intestinal fibrosis—one step towards clinical trials for stricturing inflammatory bowel disease;Giuffrida;United European Gastroenterol J,2016

5. Crohn’s disease complicated by strictures: a systematic review;Rieder;Gut,2013

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process;Journal of Crohn's and Colitis;2023-11-29

2. Therapeutic Targeting of Intestinal Fibrosis in Crohn’s Disease;Cells;2022-01-26

3. Outcome selection for tissue-agnostic drug trials for immune-mediated inflammatory diseases: a systematic review of core outcome sets and regulatory guidance;Trials;2022-01-15

4. Impedance Planimetry for Crohn's Disease Anastomotic Stricture Characterization: A Predictor of Treatment Response?;ACG Case Reports Journal;2022-01

5. Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease;Gastroenterology;2022-01